Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non–Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial
Roy S. Herbst, Yi‐Long Wu, Thomas John, et al.
Journal of Clinical Oncology (2023) Vol. 41, Iss. 10, pp. 1830-1840
Open Access | Times Cited: 229

Showing 26-50 of 229 citing articles:

Targeted therapeutic options in early and metastatic NSCLC-overview
Gabriella Gálffy, Éva Morócz, Réka Korompay, et al.
Pathology & Oncology Research (2024) Vol. 30
Open Access | Times Cited: 6
New Treatment Options for Patients With Oncogene-Addicted Non–Small Cell Lung Cancer Focusing on EGFR-Mutant Tumors
Stephanie P.L. Saw, Xiuning Le, Lizza E.L. Hendriks, et al.
American Society of Clinical Oncology Educational Book (2024) Vol. 44, Iss. 3
Closed Access | Times Cited: 6
Synergistic anticancer effects of ginsenoside CK and gefitinib against gefitinib-resistant NSCLC by regulating the balance of angiogenic factors through HIF-1α/VEGF
Xiaoping Song, Lina Wang, Panpan Cai, et al.
Toxicology and Applied Pharmacology (2024) Vol. 486, pp. 116938-116938
Closed Access | Times Cited: 6
Top advances of the year: Targeted therapy for lung cancer
Maisam Makarem, Pasi A. Jänne
Cancer (2024) Vol. 130, Iss. 19, pp. 3239-3250
Closed Access | Times Cited: 6
Adjuvant Treatments for Surgically Resected Non–Small Cell Lung Cancer Harboring EGFR Mutations
Antonio Passaro, Tony Mok, Ilaria Attili, et al.
JAMA Oncology (2023) Vol. 9, Iss. 8, pp. 1124-1124
Closed Access | Times Cited: 16
Three-Year Safety, Tolerability, and Health-Related Quality of Life Outcomes of Adjuvant Osimertinib in Patients With Resected Stage IB to IIIA EGFR-Mutated NSCLC: Updated Analysis From the Phase 3 ADAURA Trial
Thomas John, Christian Grohé, Jonathan W. Goldman, et al.
Journal of Thoracic Oncology (2023) Vol. 18, Iss. 9, pp. 1209-1221
Open Access | Times Cited: 16
International expert consensus on diagnosis and treatment of lung cancer complicated by chronic obstructive pulmonary disease
Chengzhi Zhou, Yinyin Qin, Wei Zhao, et al.
Translational Lung Cancer Research (2023) Vol. 12, Iss. 8, pp. 1661-1701
Open Access | Times Cited: 14
A Review of Biomarkers and Their Clinical Impact in Resected Early-Stage Non-Small-Cell Lung Cancer
Weibo Cao, Quanying Tang, Jingtong Zeng, et al.
Cancers (2023) Vol. 15, Iss. 18, pp. 4561-4561
Open Access | Times Cited: 14
Rapid Advances in Resectable Non–Small Cell Lung Cancer
Howard West, Jae Y. Kim
JAMA Oncology (2023) Vol. 10, Iss. 2, pp. 249-249
Closed Access | Times Cited: 13
Perioperative Immunotherapy for Non-Small Cell Lung Cancer: Practical Application of Emerging Data and New Challenges
Angelica D’Aiello, Brendon M. Stiles, Nitin Ohri, et al.
Clinical Lung Cancer (2024) Vol. 25, Iss. 3, pp. 197-214
Closed Access | Times Cited: 5
Early-Stage Non-Small Cell Lung Cancer: Prevalence of Actionable Alterations in a Monocentric Consecutive Cohort
Rossella Bruno, Anello Marcello Poma, Martina Panozzi, et al.
Cancers (2024) Vol. 16, Iss. 7, pp. 1410-1410
Open Access | Times Cited: 5
American Radium Society Appropriate Use Criteria for Unresectable Locally Advanced Non–Small Cell Lung Cancer
George Rodrigues, Kristin Higgins, Andreas Rimner, et al.
JAMA Oncology (2024) Vol. 10, Iss. 6, pp. 799-799
Closed Access | Times Cited: 5
Management of Stage III Non–Small Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update
Megan E. Daly, Navneet Singh, Nofisat Ismaila, et al.
Journal of Clinical Oncology (2024) Vol. 42, Iss. 25, pp. 3058-3060
Closed Access | Times Cited: 5
Early-Stage Non-Small Cell Lung Cancer: New Challenges with Immune Checkpoint Blockers and Targeted Therapies
Pernelle Lavaud, Martina Bortolot, Lodovica Zullo, et al.
Cancers (2024) Vol. 16, Iss. 16, pp. 2779-2779
Open Access | Times Cited: 5
Real‐world comprehensive diagnosis and “Surgery + X” treatment strategy of early‐stage synchronous multiple primary lung cancer
Danting Zhou, Tianyu Yao, Xiaojie Huang, et al.
Cancer Medicine (2023) Vol. 12, Iss. 12, pp. 12996-13006
Open Access | Times Cited: 11
Recurrence-Free Survival in Patients With Surgically Resected Non-Small Cell Lung Cancer
Ravi Rajaram, Qing Huang, Richard Z. Li, et al.
CHEST Journal (2023) Vol. 165, Iss. 5, pp. 1260-1270
Open Access | Times Cited: 11
Furmonertinib for EGFR-mutant advanced non-small cell lung cancer: a glittering diamond in the rough of EGFR-TKI
Jianghua Ding, Xingjing Ding, Jiao Zeng, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 4
Oral Decoctions Based on Qi-Yin Syndrome Differentiation After Adjuvant Chemotherapy in Resected Stage ΙΙΙA Non-Small Cell Lung Cancer: A Randomized Controlled Trial
Yi Jiang, Fangfang Liu, Yuqing Cai, et al.
Integrative Cancer Therapies (2024) Vol. 23
Open Access | Times Cited: 4
Osimertinib after definitive chemoradiotherapy in unresectable stage III epidermal growth factor receptor-mutated non-small-cell lung cancer: analyses of central nervous system efficacy and distant progression from the phase III LAURA study
Shun Lü, M-J Ahn, Thanyanan Reungwetwattana, et al.
Annals of Oncology (2024) Vol. 35, Iss. 12, pp. 1116-1125
Open Access | Times Cited: 4
Actualités dans le cancer broncho-pulmonaire : traitements médicaux
Gérard Zalcman
Bulletin de l Académie Nationale de Médecine (2025)
Closed Access
Prevalence of EGFR Mutations in Patients With Resected Stage I to III Nonsquamous Non–Small Cell Lung Cancer: Results of India Cohort
Ullas Batra, Kumar Prabhash, Vanita Noronha, et al.
JCO Global Oncology (2025), Iss. 11
Closed Access
Thérapies moléculaires ciblées en cancérologie pulmonaire
Alice Mogenet, Laurent Greillier, Pascale Tomasini
Encyclopédie médico-chirurgicale. Pneumologie (2025) Vol. 36, Iss. 1, pp. 1-9
Closed Access
Advances in adjuvant therapy for operable N2 non-small cell lung cancer: a narrative review
Lei Liu, Yan‐Ping Mao, Leilei Guo, et al.
Frontiers in Oncology (2025) Vol. 14
Open Access
Burdens of Tracheal, Bronchus, and Lung Cancer From 1990 to 2021 in China Compared to the Global Projection of 2036: Findings From the 2021 Global Burden of Disease Study
Y L Chen, Qingpeng Zeng, Muyu Li, et al.
Thoracic Cancer (2025) Vol. 16, Iss. 2
Open Access
Surgery versus concurrent chemoradiotherapy for stage III non-small cell lung cancer: a retrospective study with propensity score matching
Takao Shigenobu, Yuri Taniguchi, Takahiro Suzuki, et al.
BMC Cancer (2025) Vol. 25, Iss. 1
Open Access

Scroll to top